LYT-100 (deupirfenidone)

LYT-100 has shown a 50% reduction in gastro-intestinal (GI)-related adverse events (AEs) in
a head-to-head study versus pirfenidone. We believe the differentiated tolerability profile of
LYT-100 will address one of the key reasons that patients on the current standard of care
treatments must dose reduce, discontinue or switch from otherwise efficacious
treatments.2,3 We have also been able to dose LYT-100 at a higher exposure level, but with
a lower Cmax, than the FDA-approved dosage of pirfenidone, potentially enabling improved
efficacy. Given this, we believe LYT-100 has the potential to become standard of care and to
become a backbone therapy in the treatment for IPF.
Pirfenidone (Esbriet®) is approved for the treatment of IPF in the US and other countries.
Pirfenidone has been shown to slow the decline of lung function and research suggests it
extends life by approximately 3 years in patients with IPF.4 It is one of two standard of care
treatments for IPF, with nintedanib (OFEV®) being the other.